Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Genmab 10 Sponsored ADR Ord Shs GMAB

Healthcare Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GMAB)

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

Business Wire 10 days ago

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Business Wire October 18, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq - MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq - SMLR)

GlobeNewswire October 7, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq - MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq - SMLR)

GlobeNewswire September 29, 2025

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Business Wire September 29, 2025

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Business Wire September 3, 2025

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

Business Wire August 26, 2025

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Business Wire August 7, 2025

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Business Wire June 15, 2025
View More News ››

Opinion & Analysis (NDAQ:GMAB)

Two Approvals Underscore Biotech's Pipeline Quality

Streetwise Reports January 30, 2020
View More Opinion ››

Bullboard Posts (NDAQ:GMAB)

Diamond in the rough

Been buying in mid-19's. Went to a lecture at BWH on their new drug for myeloma. They said it was a miracle drug. Awesome stock. No...
MORGUE1 - September 11, 2014
View more Bullboard ››

SEGO Resources Inc.

SEGO Resources Inc.

SEGO Resources Inc. is a Canada-based exploration stage company. The Company is engaged in the acquisition, exploration, and ...
View More »